Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
132 Leser
Artikel bewerten:
(0)

Active-Investors: Wired News - Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-B

Stock Monitor: Magellan Health Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 01, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=ANTM as the Company's latest news hit the wire. On February 27, 2018, the New York based biopharmaceutical Company declared that the Company has successfully activated sixteen clinical trial sites in the pivotal Phase-3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Magellan Health, Inc. (NASDAQ: MGLN), which also belongs to the Healthcare sector as the Company Actinium Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/'symbol=MGLN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Actinium Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/'symbol=ANTM

The sixteen clinical trial sites in the Phase-3 SIERRA trial represent over one-third of bone marrow transplant volume in the US, and the sites are some of the leading and highest volume Bone marrow transplantation (BMT) centers in the country. The fifteenth SIERRA clinical trial site was activated at the end of October 2017.

Actinium to Provide Enrollment and Data Monitoring Safety Board Related Updates During 2018

Sandesh Seth, Chairman and Chief Executive Officer of Actinium, stated that participation of these leading US transplant centers in the SIERRA trial reflects strongly on the prospects for the Company's leading drug candidate, Iomab-b.

Sandesh added that Actinium expects to provide several enrollment and Data Monitoring Safety Board related updates during 2018 and top-line results next year. The Company is believed to making solid progress toward meeting these goals with the addition of additional sites and participation of these prestigious institutions.

SIERRA Trial

The SIERRA trial, the first multi-center, Actinium sponsored trial for Iomab-B, is planned to enroll 150 patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above and will compare Iomab-B and a BMT to physician's choice of salvage chemotherapy. The primary endpoint of the trial is durable complete remission (dCR) of at least six months and the secondary endpoint will be overall survival at one year. Iomab-B is intended to provide safer myeloablation of the bone marrow prior to a bone marrow transplant, thus providing a potentially curative treatment option for this patient population and for patients with other leukemias, lymphomas, myelomas and other blood disorders.

Actinium expects to provide updates on the Iomab-B SIERRA trial in-line with previously stated objectives for 2018 and 2019. The SIERRA trial will have three safety analyses by an independent Data Monitoring Committee when 25%, 50%, and 75% patient enrollment has been reached.

DMC Recommended Continuation of Patient Enrolment in Phase-3 SIERRA Trial

In December 2017, the Independent Data Monitoring Committee (DMC) for the Pivotal Phase-3 SIERRA Trial of Iomab-B completed its review of the data available from the trial at time of analysis. The DMC recommended that the trial could continue to enroll patients as planned. DMC reviewed initial safety data from the first 20 patients enrolled in the trial at its scheduled meeting in November 2017. Actinium would complete patient enrollment by the end of 2018.

About Iomab-B

Iomab-B, Actinium's lead product candidate, is currently being studied in pivotal Phase-3 clinical trial in patients with relapsed or refractory AML who are age 55 and above. Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Iomab-B targets cells that express CD45, a pan-leukocytic antigen widely expressed on white blood cells with the monoclonal antibody, BC8, labeled with the radioisotope, iodine-131. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient's cancer and marrow cells.

About Actinium Pharmaceuticals, Inc.

Founded in 2000 and headquartered in New York City, New York, Actinium Pharmaceuticals is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company's s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively.

Stock Performance Snapshot

February 28, 2018 - At Wednesday's closing bell, Actinium Pharma's stock dropped 4.44%, ending the trading session at $0.43.

Volume traded for the day: 1.04 million shares, which was above the 3-month average volume of 717.77 thousand shares.

After yesterday's close, Actinium Pharma's market cap was at $35.18 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.